IL17/IL17RA as a Novel Signaling Axis Driving Mesenchymal Stem Cell Therapeutic Function in Experimental Autoimmune Encephalomyelitis
Authors:
- Mónica KurteMKMónica Kurte
- Patricia Luz-CrawfordPLPatricia Luz-Crawford
- Ana María Vega-LetterAVAna María Vega-Letter
- Rafael A. ContrerasRCRafael A. Contreras
- Gautier TejedorGTGautier Tejedor
- Roberto Elizondo-VegaRERoberto Elizondo-Vega
- Fernando E. FigueroaFFFernando E. Figueroa
- Christian JorgensenChristian Jorgensen
- Farida DjouadFarida Djouad
- Flavio CarriónFCFlavio Carrión
Open Access
- 30 April 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 802
Abstract
The therapeutic effect of mesenchymal stem cells (MSCs) in multiple sclerosis (MS) and the experimental autoimmune encephalomyelitis (EAE) model has been well described. This effect is, in part, mediated through the inhibition of IL17-producing cells and the generation of regulatory T cells. While proinflammatory cytokines such as IFNγ, TNFα, and IL1β have been shown to enhance MSCs immunosuppressive function, the role of IL17 remains poorly elucidated. The aim of this study was, therefore, to investigate the role of the IL17/IL17R pathway on MSCs immunoregulatory effects focusing on Th17 cell generation in vitro and on Th17-mediated EAE pathogenesis in vivo. In vitro, we showed that the immunosuppressive effect of MSCs on Th17 cell proliferation and differentiation is partially dependent on IL17RA expression. This was associated with a reduced expression level of MSCs immunosuppressive mediators such as VCAM1, ICAM1, and PD-L1 in IL17RA−/− MSCs as compared to wild-type (WT) MSCs. In the EAE model, we demonstrated that while WT MSCs significantly reduced the clinical scores of the disease, IL17RA−/− MSCs injected mice exhibited a clinical worsening of the disease. The disability of IL17RA−/− MSCs to reduce the progression of the disease paralleled the inability of these cells to reduce the frequency of Th17 cells in the draining lymph node of the mice as compared to WT MSCs. Moreover, we showed that the therapeutic effect of MSCs was correlated with the generation of classical Treg bearing the CD4+CD25+Foxp3+ signature in an IL17RA-dependent manner. Our findings reveal a novel role of IL17RA on MSCs immunosuppressive and therapeutic potential in EAE and suggest that the modulation of IL17RA in MSCs could represent a novel method to enhance their therapeutic effect in MS.Keywords
This publication has 49 references indexed in Scilit:
- Adipose Stromal Vascular Fraction-Mediated Improvements at Late-Stage Disease in a Murine Model of Multiple SclerosisStem Cells, 2016
- Inhibition of Interferon Regulatory Factor 4 Suppresses Th1 and Th17 Cell Differentiation and Ameliorates Experimental Autoimmune EncephalomyelitisScandinavian Journal of Immunology, 2015
- Anti–IL-17A Treatment Reduces Clinical Score and VCAM-1 Expression Detected by in Vivo Magnetic Resonance Imaging in Chronic Relapsing EAE ABH MiceThe American Journal of Pathology, 2013
- Increase in Th17 and T-reg Lymphocytes and Decrease of IL22 Correlate with the Recovery Phase of Acute EAE IN RatPLOS ONE, 2011
- Animal Models of Multiple Sclerosis2009
- IL-17 Plays an Important Role in the Development of Experimental Autoimmune EncephalomyelitisThe Journal of Immunology, 2006
- Induction of Experimental Autoimmune Encephalomyelitis in IL-12 Receptor-β2-Deficient Mice: IL-12 Responsiveness Is Not Required in the Pathogenesis of Inflammatory Demyelination in the Central Nervous SystemThe Journal of Immunology, 2003
- Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitisNature Medicine, 2002
- IL‐17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL‐17F, and implications for receptor bindingThe EMBO Journal, 2001
- Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosisMultiple Sclerosis Journal, 1999